NeuroBo Pharmaceuticals (NRBO) Competitors $0.70 +0.01 (+1.78%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock NRBO vs. JNVR, WVFC, BTOG, GREE, CNF, ANY, BTCT, ARBK, LMFA, and SNTGShould you be buying NeuroBo Pharmaceuticals stock or one of its competitors? The main competitors of NeuroBo Pharmaceuticals include Janover (JNVR), WVS Financial (WVFC), Bit Origin (BTOG), Greenidge Generation (GREE), CNFinance (CNF), Sphere 3D (ANY), BTC Digital (BTCT), Argo Blockchain (ARBK), LM Funding America (LMFA), and Sentage (SNTG). These companies are all part of the "banking" industry. NeuroBo Pharmaceuticals vs. Its Competitors Janover WVS Financial Bit Origin Greenidge Generation CNFinance Sphere 3D BTC Digital Argo Blockchain LM Funding America Sentage Janover (NASDAQ:JNVR) and NeuroBo Pharmaceuticals (NASDAQ:NRBO) are both small-cap banking companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment. Which has more risk & volatility, JNVR or NRBO? Janover has a beta of -7.59, suggesting that its share price is 859% less volatile than the S&P 500. Comparatively, NeuroBo Pharmaceuticals has a beta of -0.26, suggesting that its share price is 126% less volatile than the S&P 500. Do institutionals & insiders hold more shares of JNVR or NRBO? 0.5% of Janover shares are owned by institutional investors. Comparatively, 1.4% of NeuroBo Pharmaceuticals shares are owned by institutional investors. 53.9% of Janover shares are owned by company insiders. Comparatively, 1.1% of NeuroBo Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is JNVR or NRBO more profitable? NeuroBo Pharmaceuticals has a net margin of 0.00% compared to Janover's net margin of -187.64%. Janover's return on equity of -71.96% beat NeuroBo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Janover-187.64% -71.96% -63.83% NeuroBo Pharmaceuticals N/A -189.12%-122.31% Which has better earnings & valuation, JNVR or NRBO? Janover has higher revenue and earnings than NeuroBo Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJanover$2.10M13.24-$3.37M-$1.94-9.07NeuroBo PharmaceuticalsN/AN/A-$12.47MN/AN/A Does the media prefer JNVR or NRBO? In the previous week, Janover's average media sentiment score of 0.00 equaled NeuroBo Pharmaceuticals'average media sentiment score. Company Overall Sentiment Janover Neutral NeuroBo Pharmaceuticals Neutral SummaryJanover beats NeuroBo Pharmaceuticals on 5 of the 8 factors compared between the two stocks. Get NeuroBo Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRBO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRBO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRBO vs. The Competition Export to ExcelMetricNeuroBo PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.00M$859.67M$5.75B$10.27BDividend YieldN/A4.84%5.72%4.60%P/E RatioN/A1.1874.9226.41Price / SalesN/A121.58457.0188.61Price / CashN/A19.5625.8129.91Price / Book0.466.6713.256.28Net Income-$12.47M-$4.13M$3.29B$270.38M7 Day Performance0.87%2.23%0.47%2.70%1 Month Performance8.73%8.23%4.59%5.99%1 Year Performance-80.72%26.55%73.41%25.94% NeuroBo Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRBONeuroBo PharmaceuticalsN/A$0.70+1.8%N/A-80.7%$6.00MN/A0.0010Gap UpJNVRJanoverN/A$15.00+0.3%N/A+328.9%$23.70M$2.10M-5.8622Gap UpHigh Trading VolumeWVFCWVS Financial1.4425 of 5 stars$12.18+0.2%N/A+0.9%$23.07M$5.13M12.4320BTOGBit Origin0.3569 of 5 stars$0.38-7.7%N/A-78.7%$22.67M$2.89M0.0010News CoverageShort Interest ↓Gap DownGREEGreenidge GenerationN/A$1.35+6.7%N/A-20.6%$21.15M$59.53M0.00680Gap UpCNFCNFinance2.8488 of 5 stars$3.06-7.7%N/A-72.0%$20.96M$205.99M9.85900Short Interest ↑High Trading VolumeANYSphere 3D2.3004 of 5 stars$0.69+8.7%$3.00+334.8%-20.5%$19.54M$10.83M-1.1320Positive NewsBTCTBTC Digital1.6229 of 5 stars$2.58+2.4%N/A+94.4%$19.40M$11.68M0.0016Gap DownARBKArgo Blockchain1.0575 of 5 stars$0.24+1.9%N/A-76.9%$17.35M$47.02M-0.2540Positive NewsGap DownLMFALM Funding America3.2436 of 5 stars$1.12-1.8%$5.00+346.4%-52.1%$17.02M$11M-0.268SNTGSentage0.8264 of 5 stars$5.76-15.4%N/A+16.9%$16.19M$110K0.0020Gap DownHigh Trading Volume Related Companies and Tools Related Companies Janover Alternatives WVS Financial Alternatives Bit Origin Alternatives Greenidge Generation Alternatives CNFinance Alternatives Sphere 3D Alternatives BTC Digital Alternatives Argo Blockchain Alternatives LM Funding America Alternatives Sentage Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRBO) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroBo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroBo Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.